Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 23Recruiting 4Terminated 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 15INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Tumor-Agnostic 1

Conditions

Prostate Cancer Metastatic 1Neoplasms 1Castrate-Resistant Prostate Cancer 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × cabazitaxel × Clear all
NCT02379390 2019-06-21

PRIMCAB

Sanofi

Phase 2 Terminated
8 enrolled 8 charts
Genitourinary

Prostate Cancer Metastatic

NCT01083615 2016-10-12

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Achieve Life Sciences

Phase 3 Terminated
14 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

NCT01001221 2013-09-11

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

Sanofi

Phase 1/2 Terminated
19 enrolled 55 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡